Skip to main content
H.R. 2087 116th Congress House

Drug Price Transparency Act

Official title: To amend title XVIII of the Social Security Act to require certain manufacturers to report drug pricing information with respect to drugs under the Medicare program, and for other purposes.

Introduced: April 4, 2019 Introduced by: Lloyd Doggett Democratic · Texas See on congress.gov
Health Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightConsumer affairs
More subjectsShow fewer subjects
Health care costs and insuranceHealth information and medical recordsInsurance industry and regulationMedicarePrescription drugsRetail and wholesale trades
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 21, 2019
Subcommittee Hearings Held.
Apr 5, 2019
Referred to the Subcommittee on Health.
Apr 4, 2019
Referred to the Subcommittee on Health.
Apr 4, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 4, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action May 21, 2019

Subcommittee Hearings Held.

 Plain-English summary Congressional Research Service

Drug Price Transparency Act

This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.

 Related & companion bills 6
  • HR 19 Lower Costs, More Cures Act of 2019
  • HR 2113 Prescription Drug STAR Act
  • HR 2296 More Efficient Tools to Realize Information for Consumers Act
  • S 2051 Strengthening Average Sales Price Reporting Act of 2019
  • S 3129 Lower Costs, More Cures Act of 2019
  • HR 1570 Removing Barriers to Colorectal Cancer Screening Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Cosponsors 1
All 1 Republican 1
R
Buchanan, Vern
Florida · Apr 4, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 2087: Drug Price Transparency Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-2087/
MLA
"H.R. 2087: Drug Price Transparency Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-2087/.
Bluebook (legal)
H.R. 2087, 116th Cong. (2026), https://openamerica.io/bill/116-HR-2087/.
Markdown link
[H.R. 2087: Drug Price Transparency Act](https://openamerica.io/bill/116-HR-2087/)
Report a problem